These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24053621)

  • 21. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
    Hayes JH; Barry MJ
    JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial.
    Lewicki P; Shoag J; Golombos DM; Oromendia C; Ballman KV; Halpern JA; Stone BV; O'Malley P; Barbieri CE; Scherr DS
    J Urol; 2017 Apr; 197(4):1014-1019. PubMed ID: 27836710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial.
    Landy R; Houghton LC; Berg CD; Grubb RL; Katki HA; Black A
    Cancer Prev Res (Phila); 2020 Apr; 13(4):367-376. PubMed ID: 31996370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
    Pierre-Victor D; Pinsky PF
    JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.
    Tsodikov A; Gulati R; Heijnsdijk EAM; Pinsky PF; Moss SM; Qiu S; de Carvalho TM; Hugosson J; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; Feuer EJ; de Koning HJ; Mariotto AB; Etzioni R
    Ann Intern Med; 2017 Oct; 167(7):449-455. PubMed ID: 28869989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
    Grubb RL; Pinsky PF; Greenlee RT; Izmirlian G; Miller AB; Hickey TP; Riley TL; Mabie JE; Levin DL; Chia D; Kramer BS; Reding DJ; Church TR; Yokochi LA; Kvale PA; Weissfeld JL; Urban DA; Buys SS; Gelmann EP; Ragard LR; Crawford ED; Prorok PC; Gohagan JK; Berg CD; Andriole GL
    BJU Int; 2008 Dec; 102(11):1524-30. PubMed ID: 19035857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of PLCO control arm contamination on perceived PSA screening efficacy.
    Gulati R; Tsodikov A; Wever EM; Mariotto AB; Heijnsdijk EA; Katcher J; de Koning HJ; Etzioni R
    Cancer Causes Control; 2012 Jun; 23(6):827-35. PubMed ID: 22488488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Oken MM; Marcus PM; Hu P; Beck TM; Hocking W; Kvale PA; Cordes J; Riley TL; Winslow SD; Peace S; Levin DL; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Dec; 97(24):1832-9. PubMed ID: 16368945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer.
    Palma A; Lounsbury DW; Schlecht NF; Agalliu I
    Am J Epidemiol; 2016 Feb; 183(3):227-36. PubMed ID: 26702631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.
    Weissfeld JL; Schoen RE; Pinsky PF; Bresalier RS; Doria-Rose VP; Laiyemo AO; Church T; Yokochi LA; Yurgalevitch S; Rathmell J; Andriole GL; Buys S; Crawford ED; Fouad M; Isaacs C; Lamerato L; Reding D; Prorok PC; Berg CD;
    J Natl Cancer Inst; 2012 Feb; 104(4):280-9. PubMed ID: 22298838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
    Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
    J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mortality results from a randomized prostate-cancer screening trial.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Gelmann EP; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Clapp JD; Rathmell JM; Riley TL; Hayes RB; Kramer BS; Izmirlian G; Miller AB; Pinsky PF; Prorok PC; Gohagan JK; Berg CD;
    N Engl J Med; 2009 Mar; 360(13):1310-9. PubMed ID: 19297565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate Cancer Incidence and Mortality in Relationship to Family History of Prostate Cancer; Findings From The PLCO Trial.
    Abdel-Rahman O
    Clin Genitourin Cancer; 2019 Aug; 17(4):e837-e844. PubMed ID: 31213414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Impact of PSA screening on mortality. PLCO project team (prostate, lung, colorectal, ovarian cancer screening trial)].
    Heidenreich A; Nitschmann S
    Internist (Berl); 2010 Feb; 51(2):219-20. PubMed ID: 20107755
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Andriole GL
    Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.
    Kim EH; Andriole GL; Crawford ED; Sjoberg DD; Assel M; Vickers AJ; Lilja H
    J Urol; 2017 Apr; 197(4):1041-1047. PubMed ID: 27810449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.